The week in pharma: action, reaction and insight – week to April 15, 2022

17 April 2022

By Barbara Obstoj-Cardwell. Editor

Among notable news last week, US biotech Seagen won a $41.8 million award through a US District Court ruling in its patent dispute with Japan’s Daiichi Sankyo over cancer drug Enhertu. USA-based Veru scored a big hit with Phase III data for its COVID-19 treatment candidate sabizabulin. On the M&A front, UK pharma major GlaxoSmithKline last Wednesday announced a $1.9 billion acquisition of Sierra Oncology, along with its myelofibrosis candidate momelotinib. Also announcing an M&A deal last Wednesday was specialty pharma company Halozyme Therapeutics, with a $960 million bid for Antares Pharma.

Seagen prevails n Texas lawsuit setting stage for arbitration decision

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK